Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03038087 · ClinicalTrials.gov registry record · NA
A Study to Test the SENSE Device in Patients With Intracranial Hemorrhage
A NA study, sponsored by Sense Diagnostics.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT03038087: Completed NA study, sponsored by Sense Diagnostics.
NCT03038087 is a NA study that has completed, run by Sense Diagnostics. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03038087, a NA study, has completed, sponsored by Sense Diagnostics.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out whether a device for monitoring bleeding in patients with acute hemorrhagic stroke will show similar findings as CT scans performed to evaluate the stroke.
Primary Outcome
Number of subjects who experienced a serious device-related adverse event or seizure.
Interventions
- DEVICE SENSE Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-02-23 |
| Est. Completion | 2017-12-31 |
| Phase | NA |
What the finished NCT03038087 record still lists
NCT03038087 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which SENSE Device is the first listed.
NCT03038087 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03038087 about?
NCT03038087 is a clinical study titled "A Study to Test the SENSE Device in Patients With Intracranial Hemorrhage". The purpose of this research study is to find out whether a device for monitoring bleeding in patients with acute hemorrhagic stroke will show similar findings as CT scans performed to evaluate the stroke.
What is the current status of trial NCT03038087?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2017-02-23. Estimated completion is 2017-12-31.
What interventions are being tested in trial NCT03038087?
The interventions under investigation include: SENSE Device (DEVICE).
Who is sponsoring clinical trial NCT03038087?
This trial is sponsored by Sense Diagnostics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03038087's enrollment target sits among peer trials
10 1927th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI